“Good Will Toward Men” (Luke 2 14)

1917 ◽  
Vol 10 (1) ◽  
pp. 52-56 ◽  
Author(s):  
James Hardy Ropes

Professor Adolf von Harnack in the Sitzungsberichte of the Berlin Academy for December 9, 1915 (pages 854–875) has discussed afresh in his characteristically interesting and instructive fashion the textual criticism and meaning of the angels' song in Luke 2 14. After a full exposition of the evidence and an investigation of the rare word εὐδοκία, he decides for the following text:Δόξα ἐν ὑΨίστοις ϑεῷ καὶ ἐπὶ γῆςΕἰρήνη ἀνϑρώποις εὐδοκίας,which he translates:“Glory in the highest to God and on earthPeace to men of (His) gracious will.”This form of the Greek text is in the second line substantially that on which the English Revised Version rests (“men in whom he is well pleased”); but Harnack, following Origen, connects εὐδοκίας not with ἀνϑρώποις but, by a somewhat harsh hyperbaton, with εἰρήνη, and interprets: “Peace is now given to men—no ordinary peace but the peace of His gracious will.”Harnack's argument, which contains much valuable discussion on various aspects of the verse, need not be here repeated. But two of the points which he makes, and in regard to which his reasoning is convincing, deserve notice; for although at first sight they might appear to occupy but a modest place among his results, in reality they seem to offer the key to the serious textual problem of the passage, and so lead to a translation and interpretation quite different from Harnack's. They may be stated thus:(1) With the reading εὐδοκίας, the song is a distich, of which the first line must be taken to include the words ἐπὶ γῆς and the second to begin with εἰρήνη.(2) ἀνϑρώποις εὐδοκίας is a phrase wholly unexampled and in itself full of difficulty. For εὐδοκία means “God's gracious will.” It refers to His purpose, His choice, not to His approval or satisfaction with man's performance; and it looks to the future, to grace, to the hope of a needy world, not to the past, to man's merit, or even to the inherent worth of human nature.

Author(s):  
Pasi Heikkurinen

This article investigates human–nature relations in the light of the recent call for degrowth, a radical reduction of matter–energy throughput in over-producing and over-consuming cultures. It outlines a culturally sensitive response to a (conceived) paradox where humans embedded in nature experience alienation and estrangement from it. The article finds that if nature has a core, then the experienced distance makes sense. To describe the core of nature, three temporal lenses are employed: the core of nature as ‘the past’, ‘the future’, and ‘the present’. It is proposed that while the degrowth movement should be inclusive of temporal perspectives, the lens of the present should be emphasised to balance out the prevailing romanticism and futurism in the theory and practice of degrowth.


2011 ◽  
Vol 1 (2) ◽  
pp. 266-291 ◽  
Author(s):  
Rukmini Bhaya Nair

Over the past half-century, Noam Chomsky has established a powerful intellectual presence in two apparently unrelated domains of discourse — the field of theoretical linguistics and the arena of anti-establishment politics. This paper examines Chomsky’s use of metaphor across these domains, arguing that in Chomsky’s work metaphor enables an undercover, perhaps even classically ‘anarchic’ dialogue between disciplines. Organizationally as well as psychologically, the two major inquiries into human nature undertaken by him are, the paper suggests, structured and unified in relation to each other via the seemingly innocuous agency of metaphor. The paper also traces Chomsky’s innovative production of metaphors to engage in dialogue with both the past and the future. To reconstruct Chomsky through his metaphors is to attempt to read him not as a doctrinaire Cartesian but as someone who has responded with extreme ‘context-sensitivity’ to changing circumstances in both his fields. Finally, the paper contends that a study of Chomsky’s metaphorical practice could, inter alia, offer unprecedented insights into the creative and essentially unified thought processes of a major 20th century thinker.


Pharmaceutics ◽  
2018 ◽  
Vol 10 (3) ◽  
pp. 105 ◽  
Author(s):  
Serge Mignani ◽  
Rama Tripathi ◽  
Liang Chen ◽  
Anne-Marie Caminade ◽  
Xiangyang Shi ◽  
...  

Tuberculosis (TB) is a contagious infection that usually attacks not only the lungs, but also brain and spine. More than twenty drugs have been developed for the treatment of TB, but most of them were developed some years ago. They are used in different combinations. Isoniazid and Rifampicin are examples of the five first line TB drugs, whereas, for instance, Levofloxacin, Kanamycin and Linezolid belong to the second line drugs that are used for the treatment of drug resistant TB. Several new bicyclic nitroimidazoles (e.g., Delamanid) without mutagenic effects were developed. New TB drugs need to provide several main issues such as more effective, less toxic, and less expensive for drug resistant TB. Besides polymeric, metal-based nanoparticles, polymeric micelles and polymers, dendrimer nanostructures represent ideal delivery vehicles and offer high hopes for the future of nanomedicine. In this original review, we present and analyze the development of anti-TB drugs in combination with dendrimers. Few articles have highlighted the encapsulation of anti-TB drugs with dendrimers. Due to their unique structure, dendrimers represent attractive candidates for the encapsulation and conjugation of other anti-TB drugs presenting important drawbacks (e.g., solubility, toxicity, low bioavailability) that hinder their development, including clinic trials.


Rheumatology ◽  
2019 ◽  
Vol 58 (12) ◽  
pp. 2181-2187 ◽  
Author(s):  
Tristan Pascart ◽  
Laurène Norberciak ◽  
Hang-Korng Ea ◽  
Sahara Graf ◽  
Pascal Guggenbuhl ◽  
...  

Abstract Objective The objective was to determine the proportion of patients with difficult-to-treat or difficult-to-prevent acute gout attacks eligible for IL-1 inhibition. Methods Participants included in the French cross-sectional GOSPEL cohort (n = 1003 gout patients) were examined for contraindications and intolerance to standard of care (SoC) drugs of gout flares (colchicine, non-steroidal anti-inflammatory drugs and systemic glucocorticoids). Patients were classified as definitely eligible for first-line IL-1 inhibition (canakinumab) according to European summary of product characteristics (contraindications/intolerance to SoC and at least three flares per year) without any other anti-inflammatory options (contraindications/intolerance only), or potentially eligible (precaution of use). Eligibility to receive IL-1 during an on-going flare related to insufficient efficacy was assessed (second-line eligibility). Results Definite first-line eligibility for IL-1 therapy was found in 10 patients (1%) and contraindication to all SoC therapies in nine patients who had presented <3 flares in the past 12 months. At least precaution of use for SoC therapies was noted for 218/1003 patients (21.7%). Of 487 patients experiencing flares at baseline, 114 (23.4%) were still experiencing pain scored ⩾4/10 numeric scale on day 3, one of whom could not receive further SoC drugs. Only nine of them had three or more flares in the past year and were eligible for second-line IL-1 inhibition. Conclusion Despite significant numbers of patients without any SoC anti-inflammatory therapeutic options for gout flares, eligibility for IL-1 inhibition therapy according to current European approval is rare.


2019 ◽  
Vol 20 (1) ◽  
pp. 52-57
Author(s):  
V. L. Sinta Herindrasti

Yuval Noah Harari is a history professor of Israeli births who has written three books of best-Seller namely sapiens A Brief History of Humankind (2011), the future Homo Deus of Mankind (2015) and 21 Lessons for the 21st century (2018). If the first book tells of human life in the past, the second book is exploring the human being of the future, and then the last book sees human nature now. Sapiens first published in Hebrew in 2011 and later published in English in 2014.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14064-e14064
Author(s):  
Irfan Jawed ◽  
Julia Wilkerson ◽  
Austin G. Duffy ◽  
Antonio Tito Fojo

e14064 Background: The past 20 years have seen progress in mCRC with more effective agents and better medical, surgical and supportive care. Methods: Systematic review of 101 phase III and large phase II trials in mCRC to quantify benefit over time with first-line and subsequent therapies. Outcomes in the experimental (EA) and control arms (CA) included progression-free survival (PFS), overall response rate (ORR), stable disease (SD), and overall survival (OS). Data were analyzed according to dates of publication and median enrollment. Results: Significant outcomes are reported; most had R2 values > 0.6. OS of EA improved 0.83 mos/yr. Importantly OS of CA improved 0.58 mos/yr likely reflecting subsequent use of experimental regimens in CA and improvement in mCRC care over time. Chemotherapy has contributed only partly to gains in OS since (1) only modest improvements of PFS (0.33 [EA] and 0.26 [CA] mos/yr) and we have shown OS gains are proportional to PFS gains indicating other factors are as or more important than chemotherapy; and (2) lack of OS improvement in 14 second/subsequent line trials. Furthermore, to assess the contribution of each drug/drug class to improvement in OS we performed linear regression with OS the dependent variable versus time publication. We found oxaliplatin, irinotecan and bevacizumab have contributed to progress; but not cetuximab/panitumumab likely explained by inclusion of pts with tumors harboring mutant ras in studies. Not surprisingly, capecitabine in place of 5-fluorouracil had no impact on progress made. As expected PFS correlates highly with OS, but importantly ORR had very high correlations with both PFS and OS. SD was an “adverse” outcome, OS decreasing as SD rates increase. Conclusions: OS of mCRC patients has improved gradually over the past two decades, with gains from chemotherapy and importantly gains from other factors, including lead-time bias, better loco-regional approaches and supportive care. Gains from first line therapies have been modest but consistent; gains from second line therapies have been disappointing. We believe future progress will be more fruitful if emphasis is given to improving second line therapies.


2016 ◽  
Vol 34 (4) ◽  
pp. 358-381 ◽  
Author(s):  
Thomas F. Tierney

This essay responds to German theorist Thomas Lemke’s call for a conversation between two distinct lines of reception of Foucault’s concept of biopolitics. The first line is comprised of sweeping historical perspectives on biopolitics, such as those of Giorgio Agamben and Antonio Negri, and the second is comprised of the more temporally focused perspectives of theorists such as Paul Rabinow, Nikolas Rose, and Catherine Waldby, whose biopolitical analyses concentrate on recent biotechnologies such as genetic techniques and the biobanking of human tissues. This essay develops this conversation by bringing the two lines to bear on the neoliberal “bioeconomy” that has developed over the past three decades and uses the perspective of Italian theorist Roberto Esposito to represent the first line. Esposito’s unique combination of Foucauldian biopolitics and the Maussean gift tradition provides a critical perspective that engages and challenges the neoliberal inclination of many theorists from the second line.


Futures ◽  
2012 ◽  
Vol 44 (6) ◽  
pp. 546-552 ◽  
Author(s):  
Ernest Garcia
Keyword(s):  
The Past ◽  

Sign in / Sign up

Export Citation Format

Share Document